Multaq (dronedarone) costs roughly $24 per day, or over $7,100 per year, before insurance. That’s more than 30 times the cost of amiodarone, the closest generic alternative. The short answer for why it’s so expensive: Multaq is still protected by patents, no generic version is available yet, and the manufacturer faces no price competition.
No Generic Version Exists Yet
The single biggest factor driving Multaq’s price is that it remains a brand-only medication. When a drug has no generic competitor, the manufacturer can set the price without market pressure to lower it. Generic drugs typically cost 80% to 85% less than their brand-name counterparts, but that price drop only happens once generics actually reach pharmacy shelves.
At least one generic manufacturer, Sandoz, has received tentative FDA approval for a generic version of dronedarone 400 mg tablets. “Tentative approval” means the FDA confirmed the generic meets safety and effectiveness standards, but it cannot be sold yet because of existing patent protections. So the product is ready to go but legally blocked from the market.
Patents Block Competition Until 2029
Sanofi, the company behind Multaq, holds multiple patents listed in the FDA’s Orange Book that prevent generic competition. The key patents and their expiration dates are:
- U.S. Patent 8,410,167: expires April 16, 2029
- U.S. Patent 9,107,900: expires April 16, 2029
- U.S. Patent 8,602,215: expires June 30, 2031
Sandoz’s generic application includes a certification that it will not market its version until the 2029 patents expire. That means the earliest a generic dronedarone could hit pharmacies is sometime in 2029, and depending on how the later patent is handled, full generic competition might not arrive until mid-2031.
Sanofi also filed a patent infringement lawsuit against Sandoz in the U.S. District Court for the District of Delaware, which triggered an automatic waiting period that further delayed generic approval. That waiting period has since expired, but the underlying patent barriers remain in place.
How Multaq’s Cost Compares to Alternatives
The price gap between Multaq and other heart rhythm medications is enormous. Based on wholesale acquisition costs, a side-by-side comparison looks like this:
- Dronedarone (Multaq): $12.19 per tablet, taken twice daily, for an average daily cost of $24.38 and an annual cost of about $7,119
- Amiodarone (generic): $0.31 per tablet, taken twice daily, for an average daily cost of $0.62 and an annual cost of about $226
That’s a difference of nearly $6,900 per year. Even with insurance covering a portion, your copay or coinsurance for Multaq will almost always be significantly higher than for a generic antiarrhythmic.
Why Doctors Prescribe It Despite the Cost
Multaq was developed as a modified version of amiodarone. Amiodarone is highly effective at controlling atrial fibrillation, but it carries serious long-term risks including thyroid damage, lung toxicity, and liver problems, largely because of the iodine in its chemical structure. Dronedarone was designed without that iodine molecule specifically to reduce those toxic side effects.
For patients who need a rhythm control medication but can’t tolerate amiodarone’s side effect profile, dronedarone fills a gap that no cheap generic currently covers. This clinical niche gives Sanofi additional pricing leverage. When a drug is the only option in its specific safety category, there’s less incentive to lower the price. The drug was also used in the influential EAST-AFNET 4 trial, which helped establish early rhythm control as a strategy for atrial fibrillation, further solidifying its place in treatment guidelines.
Ways to Reduce Your Out-of-Pocket Cost
Sanofi offers a patient assistance program called Sanofi Patient Connection for people who have no insurance coverage for the drug or who can’t access it through their plan. To qualify, your household income needs to be at or below 400% of the federal poverty level. You must be a U.S. citizen or resident, and you’ll need to submit financial documentation along with your application. The program requires reapplication every 12 months with updated financial information. Patients on Medicare Part D may also be eligible, though the specifics depend on individual circumstances.
Beyond manufacturer assistance, some options worth exploring include asking your pharmacist to run the prescription through different discount programs, checking whether your insurance plan’s formulary covers Multaq at a preferred tier with prior authorization, or discussing with your cardiologist whether a therapeutic alternative might work for your situation. The cost difference between Multaq and generic amiodarone is large enough that it’s a reasonable conversation to have, weighing the safety advantages of dronedarone against the financial reality of paying for it long-term.